Literature DB >> 30793376

Kidney transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity.

Ayelet Grupper1,2, Doron Schwartz2, Roni Baruch1,2, Idit F Schwartz2, Richard Nakache1, Yaacov Goykhman1, Polina Katz1, Angelina Lebedinsky1, Ido Nachmany1, Nir Lubezky1, Jessie Aouizerate1, Moshe Shashar2,3, Helena Katchman1,4.   

Abstract

Inflammatory bowel diseases (IBD) is a systemic disorder with possible renal involvement, yet data regarding the outcome of kidney transplantation (KT) in those patients, and IBD course post KT, are scarce. In this retrospective analysis, we studied the outcome of 12 IBD kidney recipients (seven Crohn's disease, five ulcerative colitis; primary kidney disease was IgA nephropathy in five, polycystic disease in four), compared to two control groups: matched controls and a cohort of recipients with similar kidney disease. During a follow-up period of 60.1 (11.0-76.6) months (median, interquartile range), estimated 5-year survival was 80.8 vs. 96.8%, with and without IBD, respectively (P = 0.001). Risk of death with a functioning graft was higher with IBD (HR = 1.441, P = 0.048), and with increased age (HR = 1.109, P = 0.05). Late rehospitalization rate was higher in IBD [incidence rate ratio = 1.168, P = 0.030], as well as rate of hospitalization related to infection [1.42, P = 0.037]. All patients that were in remission before KT, remission was maintained. Patients that were transplanted with mild or moderate disease remained stable or improved with Infliximab or Adalimumab treatment. In conclusion, IBD is associated with an increased risk of mortality, hospitalization because of infection and late rehospitalization after KT. Clinical course of IBD is stable after KT.
© 2019 Steunstichting ESOT.

Entities:  

Keywords:  inflammatory bowel disease; kidney transplantation

Mesh:

Substances:

Year:  2019        PMID: 30793376     DOI: 10.1111/tri.13415

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  5 in total

1.  The use of anti-interleukin-1 agents and tumor necrosis factor-alpha inhibitors in renal transplant recipients.

Authors:  Veli Yazısız; Vural Taner Yılmaz; İsmail Uçar; Özgür Dandin; Bengisu Aslan; Funda Erbasan; Hüseyin Koçak; Mustafa Ender Terzioğlu
Journal:  Arch Rheumatol       Date:  2021-01-14       Impact factor: 1.472

Review 2.  Gastrointestinal complications after kidney transplantation.

Authors:  Rossella Gioco; Daniela Corona; Burcin Ekser; Lidia Puzzo; Gaetano Inserra; Flavia Pinto; Chiara Schipa; Francesca Privitera; Pierfrancesco Veroux; Massimiliano Veroux
Journal:  World J Gastroenterol       Date:  2020-10-14       Impact factor: 5.742

3.  Incidence and Impacts of Inflammatory Bowel Diseases among Kidney Transplant Recipients: A Meta-Analysis.

Authors:  Panupong Hansrivijit; Max M Puthenpura; Charat Thongprayoon; Himmat S Brar; Tarun Bathini; Karthik Kovvuru; Swetha R Kanduri; Karn Wijarnpreecha; Wisit Cheungpasitporn
Journal:  Med Sci (Basel)       Date:  2020-09-16

4.  Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation.

Authors:  Urvashi Singh; Baljit Singh; Maria Irene Bellini
Journal:  World J Transplant       Date:  2022-02-18

5.  Inflammatory Bowel Disease Is More Common in Patients with IgA Nephropathy and Predicts Progression of ESKD: A Swedish Population-Based Cohort Study.

Authors:  Johanna Rehnberg; Adina Symreng; Jonas F Ludvigsson; Louise Emilsson
Journal:  J Am Soc Nephrol       Date:  2020-11-11       Impact factor: 10.121

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.